https://cyanatx.com/ 2026-04-22 monthly 1.0 https://cyanatx.com/images/enpp1-mechanism.png ENPP1 mechanism of action — tumor immune evasion vs CY-3132 treatment https://cyanatx.com/images/pipeline-chart.png Cyana Therapeutics pipeline chart — CY-3132 and CY-3292 https://cyanatx.com/images/shoshana-shendelman.jpg Shoshana Shendelman, PhD — Co-Founder and CEO of Cyana Therapeutics https://cyanatx.com/images/jessica-dennison.png Jessica Dennison, PhD — COO of Cyana Therapeutics https://cyanatx.com/about/dr-shoshana-shendelman 2026-04-22 yearly 0.8 https://cyanatx.com/images/shoshana-shendelman.jpg Shoshana Shendelman, PhD — Co-Founder and CEO of Cyana Therapeutics https://cyanatx.com/about/dr-jessica-dennison 2026-04-22 yearly 0.8 https://cyanatx.com/images/jessica-dennison.png Jessica Dennison, PhD — COO of Cyana Therapeutics